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Background:Hypertension is a stronger predictor of hemorrhagic than ischemic strokes in the general population.
We aimed to identify whether hypertension or other risk factors, including HIV-related factors, differ in their as-
sociations with stroke subtypes in people living with HIV (PLWHIV).
Methods: HIV-1-positive individuals from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study
were followed from the time of ﬁrst blood pressure (BP) measurement after 1/1/1999 or study entry until the
ﬁrst of a validated stroke, 6 months after last follow-up or 1/2/2014. Stroke events were centrally validated using
standardized criteria. Hypertension was deﬁned as one systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg.
Poisson and Cox proportional hazards regressionmodels determined associations of established cerebro/cardiovas-
cular disease and HIV-related risk factors with stroke and tested whether these differed by stroke subtype.
Findings: 590 strokes (83 hemorrhagic, 296 ischemic, 211 unknown) occurred over 339,979 person-years (PYRS)
(incidence rate/1000 PYRS 1.74 [95% conﬁdence interval (CI) 1.60–1.88]). Common predictors of both hemorrhagic
and ischemic strokeswere hypertension (relative hazard 3.55 [95% CI 2.29–5.50] and 2.24 [1.77–2.84] respectively)
and older age (1.28 [1.17–1.39] and 1.19 [1.12–1.25]). Male gender (1.62 [1.14–2.31] and 0.60 [0.35–0.91]), previ-
ous cardiovascular events (4.03 [2.91–5.57] and 1.44 [0.66–3.16]) and smoking (1.90 [1.41–2.56] and 1.08
[0.68–1.71]) were stronger predictors of ischemic then hemorrhagic strokes, whereas hypertension, hepatitis C
(1.32 [0.72–2.40] and 0.46 [0.30–0.70]) and estimated glomerular ﬁltration rate b60 mL/min/1.72 m3 (4.80
[2.47–9.36] and 1.04 [0.67–1.60]) were stronger predictors of hemorrhagic than ischemic strokes. A CD4 count b
200 cells/μL was associated with an increased risk of hemorrhagic stroke only.
Interpretation: Risk factors for stroke may differ by subtype in PLWHIV, emphasizing the importance of further re-
search to increase the precision of stroke risk estimation.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Stroke is a major cause of mortality, morbidity and disability world-
wide. Ischemic stroke is the most common stroke subtype, accounting
for nearly 90% of all strokes, whereas hemorrhagic strokes have a higher
fatality rate [1]. In people livingwith HIV (PLWHIV), an increased risk of
cerebro/cardiovascular disease (CVD) is well documented across di-
verse clinical settings and populations [2–6]. Multiple factors are likely
to contribute to this increased risk, including a higher prevalence of
common CVD risk factors such as hypertension, diabetes, dyslipidemia,
renal impairment and smoking [2,5–8], the pro-atherogenic effects of
certain antiretroviral (ARV) drugs [4,6,9,10] and HIV-related inﬂamma-
tion, immune activation and microbial translocation [11]. In addition,
hypercoagulability and inﬂammation-induced intracranial vasculopa-
thy may also play a role [6,12,13].
Although cerebrovascular and cardiovascular diseases exhibit simi-
larities in risk factors and pathophysiology, cerebrovascular disease is
generally more heterogeneous, and ischemic and hemorrhagic strokes
have distinct risk proﬁles. In PLWHIV, the heterogeneous nature of
stroke pathophysiology and clinical presentations, which may be com-
plicated by neuro-infections mimicking stroke, means that few studies
have considered stroke outcomes; studies of hemorrhagic stroke as a
separate endpoint are limited [3,6,14] and thus, to date, most studies
in this population have considered ischemic strokes or a composite end-
point of both stroke subtypes and/or other forms of CVD [2,4,6,8]. In the
general population, several shared risk factors for ischemic and hemor-
rhagic strokes have been identiﬁed including hypertension, renal im-
pairment, age, ethnicity, diabetes, obesity and smoking [15].
Hypertension and low estimated glomerular rate (eGFR) are more
strongly linked to hemorrhagic than ischemic strokes [16,17], whereas
Research in context
Evidence before this study
Pubmed search:We used PubMed to identify previous studies
on stroke and stroke risk factors in people living with HIV, using
search terms “stroke and HIV”, “cardiovascular disease and HIV”,
“cerebrovascular disease and HIV”, “ischemic strokes and HIV”,
and “hemorrhagic strokes and HIV”. The search included studies
up to June 10, 2018, with no language restrictions. To date, most
studies on stroke in this population consider ischemic strokes
only or a composite endpoint that includes both ischemic and
hemorrhagic strokes and/or other forms of cerebro/cardiovascu-
lar disease. The etiology of increased stroke risk in people living
with HIV includes a higher prevalence of traditional cerebro/car-
diovascular disease risk factors and factors relating to immuno-
suppression and inﬂammation such as HIV-vasculopathy and
immune reconstitution.Multiple risk factors have been associated
with an increased risk of stroke, including age, hypertension, dia-
betes, dyslipidemia, smoking, hepatitis C virus, and injection drug
use. Findings are conﬂicting, however, on the importance of im-
munosuppression and viral replication for stroke risk. In the gen-
eral population it is known that ischemic andhemorrhagic strokes
have distinct risk proﬁles, and although the two types of strokes
share several common risk factors, hypertension and low esti-
mated glomerular rate have been shown to be more strongly
linked to hemorrhagic than ischemic strokes, whereas ischemic
stroke is more strongly linked tometabolic risk factors. As no pre-
vious studies on stroke risk in people living with HIV have for-
mally compared risk proﬁles for the two stroke types, it is
unknown whether hypertension, other traditional cerebro/car-
diovascular disease risk factors and/or HIV-related factors differ
signiﬁcantly in their impact on risk for ischemic versus hemor-
rhagic stroke.
Added value of this study
Five-hundred and ninety centrally validated strokes occurred
over 339,979 person-years of follow-up from 1999 to 2014. In for-
mal comparison models (83 hemorrhagic and 296 ischemic
strokes), we found the strongest common predictors to be hyper-
tension and older age. Male gender, previous cardiovascular
events, and smokingwere stronger predictors of ischemic strokes,
whereas hypertension, hepatitis C virus coinfection and estimated
glomerularﬁltration rate b60mL/min/1.72m3were stronger pre-
dictors of hemorrhagic strokes. A CD4 count b200 cells/μL was as-
sociated with a borderline increased risk of hemorrhagic but not
ischemic stroke, whereas a higher viral load and exposure to anti-
retroviral therapy were not associated with the risk of either
stroke subtype. Although we were limited by a relatively low
number of hemorrhagic strokes, ﬁndings from this large,
heterogeneous cohort with centrally validated separate stroke
endpoints suggest that some traditional and HIV-related risk fac-
tors may differ by stroke subtype in people living with HIV.
Implications of all available evidence
With thewell-documented increased risk of stroke in the HIV-
positive population, screening and preventive treatments are be-
coming increasingly important as this population is aging. As the
risk of complications (e.g. bleeding) of anti-thrombotic therapy
increases with age, stroke risk stratiﬁcation which takes into ac-
count traditional cerebro/cardiovascular risk factors as well as
HIV-related factors, may help to determine the relative beneﬁts
and risks of such therapy. Our ﬁndings indicate that the use of
stratiﬁed predictorsmay providemore precise risk estimates. Fur-
ther studies are needed to conﬁrm our ﬁndings, in order to indi-
vidualize and optimize stroke prevention and management
leading to improved outcomes.
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ischemic stroke is typically more strongly linked to metabolic risk fac-
tors [15].
As in the general population, risk factor stratiﬁcationmay be of value
in PLWHIV; risk factors may vary or have opposing effects on the two
stroke subtypes, and preventive medications, such as anti-thrombotic
therapy, have opposing effects on risk of ischemic and hemorrhagic
strokes [18]. The effects of some common CVD risk factors may, how-
ever, differ in PLWHIV, andwedonot knowwhether HIV-related factors
are also differentially associated with ischemic and hemorrhagic
strokes. As the HIV-positive population ages, and the risk of complica-
tions of anti-thrombotic therapy, such as bleeding, increases, stroke
risk stratiﬁcation which takes into account both common CVD risk fac-
tors and HIV-related factors, could be helpfulwhen determining the rel-
ative beneﬁts and risks of such therapy.
By identifying their respective risk for each stroke subtype, it may be
possible to inﬂuence clinical decision-making, individualize and opti-
mize stroke prevention and management and improve outcomes. Our
aim was to investigate systematically whether hypertension, other
common CVD risk factors and HIV-related factors were differently asso-
ciated with ischemic and hemorrhagic strokes in the D:A:D (Data Col-
lection on Adverse events of anti-HIV Drugs) Study.
2. Material and Methods
2.1. Study Design, Study Participants and Outcomes
The D:A:D Study is a large, prospective observational cohort study
which followed N49,000 HIV-1-positive persons from 11 collaborating
cohorts receiving care at 212 hospital clinics in Australia, Europe and
USA, who together contributed N450,000 person-years (PYRS) of
follow-up (for participating institutions, see Appendix). The primary
aim of the study, described previously [19], was to investigate associa-
tions between the use of ARV drugs and risk of CVD. The data collected
included information on socio-demographic factors, HIV-related and
other laboratory markers, ARV regimen/history and CVD risk factors/
treatments. Data were reported to the D:A:D coordinating center as
anonymous, computerized case report ﬁles which were then merged
into a standardized central dataset. All cases of stroke were validated
centrally by a trained medical doctor, against a validated stroke algo-
rithm (https://www.chip.dk/Portals/0/ﬁles/Study%20documents/DAD_
MOOP_revised2013.pdf) based on the presence of focal neurological
signs (with/without additional imaging), with duration N24 h and no
evidence of any non-vascular cause. Accepted stroke events were classi-
ﬁed as deﬁnite or possible depending on the level of certainty. The dif-
ferentiation of strokes into the ischemic and hemorrhagic subtypes
was undertaken based on imaging data; where imaging data were un-
available, strokes were classiﬁed as being of unknown etiology.
This analysis was conducted in accordance with the Declaration of
Helsinki, with approval by national ethics committees and informed
consent where required by national regulations. All participating co-
horts followed local national guidelines/regulations regarding patient
consent and/or ethical review. In particular, of the countries repre-
sented, only Switzerland and Australia required speciﬁc ethical ap-
proval for D:A:D in addition to that required for their national cohorts
(Swiss HIV Cohort Study and AHOD), both of which have obtained this
approval. France, Italy, and Belgium do not require speciﬁc ethical ap-
proval over-and-above that required for the individual cohorts (Nice/
Aquitaine, Brussels St. Pierre and IcoNA, respectively). Neither the
Netherlands (ATHENA) nor the United States (CPCRA) requires speciﬁc
ethical approval as data are provided as part of HIV care and as the
datasets are non-identiﬁable public use datasets. For the EuroSIDA
study (including data from the BASS and Swedish cohorts), which in-
cludes participants from many European countries, each participating
site has a contractual obligation to ensure that data collection and shar-
ing is done in accordance with national legislation; each site principal
investigator either maintains appropriate documentation from an
ethical committee (if required by law) or has a documented written
statement to say that this is not required.
2.2. Statistical Methods
We followed D:A:D Study participants from the time of the ﬁrst
blood pressure (BP) measurement from 1/1/1999 or individual study
entry until the ﬁrst of a validated stroke, 6 months after last follow-up
or 1/2/2014.We calculated incidence rates (IRs) separately for ischemic,
hemorrhagic and unknown stroke subtypes, overall and after stratiﬁca-
tion by the presence or absence of hypertension over follow-up, which
we deﬁned as a single systolic BP ≥140 mm Hg and/or diastolic BP
≥90 mm Hg (regardless of the use of anti-hypertensive medication). If
BP values subsequently changed, we also allowed the hypertensive sta-
tus of an individual to change in a time-updated manner.
After censoring the follow-up of individualswith anunknown stroke
subtype (where radiological informationwasmissing or subtype uncer-
tainty remained) at the time of the event, we initially explored whether
the associations of several factors with stroke risk differed by stroke
subtype, ﬁtting a multivariable Poisson regression model to ischemic
and hemorrhagic strokes separately. We considered the following risk
factors: socio-demographic (gender, ethnicity (both time-ﬁxed covari-
ates), age (/5 years older), calendar year), CVD-related (dyslipidemia
(deﬁned as total cholesterol ≥ 6.2 mmol/L, HDL ≤ 0.9 mmol/L, or
triglyceride ≥ 2.3 mmol/L), previous CVD event (myocardial infarction
(MI)/stroke), family history of CVD, body mass index (BMI), diabetes,
smoking status (all time-updated)) and HIV-related (mode of HIV-
acquisition (time-ﬁxed), previous AIDS diagnosis, latest HIV-RNA viral
load (VL) and CD4 count, cumulative exposure (/5 years) to protease in-
hibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs),
nucleoside reverse transcriptase inhibitors (NRTIs)), hepatitis B virus
(HBV) and hepatitis C virus (HCV) infection (all time-updated).
As these exploratory analyses did not control for competing risks, we
then formally compared the reported associations with each stroke sub-
type usingmodiﬁed Cox proportional hazardsmodels which took account
of competing risks. This allowed us to investigate whether risk factors ap-
peared to differ by stroke subtype. We compared the predictive value of
each selected risk factor for the two stroke subtypes in a model that in-
cluded adjustment for all other potential confounders, but in which only
the selected risk factor was allowed to have different associations with
the two subtypes. Thesemodels therefore allowed us to estimate the com-
mon association of each factor with the two stroke subtypes and to test
whether this association differed signiﬁcantly by stroke subtype. Note
that in order to reduce the number of statistical tests performed, we only
investigated interactions for factors that would be of direct clinical rele-
vance (for example, interactions with ‘unknown smoking status’ were
not considered) or where our exploratory analyses had suggested either
a qualitatively different association or a substantial quantitative difference
in association. Thus, formode ofHIV acquisition,we only allowed the asso-
ciation with IDU status to vary, for BMI we only allowed the lowest cate-
gory (b18 kg/m2) to vary and for smoking status, only current smoking
was allowed to vary. As some of these factors were themselves correlated
(e.g. HCV and IDU mode of HIV acquisition), we then ﬁtted models that
allowed multiple risk factors to simultaneously have subtype-speciﬁc ef-
fects, removing factors and interactions that no longer demonstrated a
strong association with the outcome.
In a sub-analysis, we additionally included Cockcroft-Gault esti-
mated eGFR as an additional time-updated covariate (2 consecutive
measurements, 3 months apart) after restricting follow-up to the start
of systematic collection of eGFR in the study (1/2/2004). Since general
population studies have normally used a deﬁnition of hypertension
that requires two consecutive elevated BP measurements [17], we also
investigated the robustness of our ﬁndings to changes in the deﬁnition
of hypertension, requiring individuals to have two consecutive elevated
BP measurements to meet the criteria.
Statistical analyses were performed using SAS v9.3.
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2.3. Role of the Funding Source
The funders had no direct role in study design, data collection, anal-
ysis, interpretation, reportwriting, or the decision to submit for publica-
tion. The corresponding author had full access to all data and had
responsibility for submission for publication.
3. Results
3.1. Characteristics of Study Participants
Of the total 43,564 individuals included, themajority of participants
with stroke were male, white, had acquired HIV through sex between
men, were current smokers and had been exposed to ARV drugs at the
time of their stroke event, whereas just under half had hypertension.
Characteristics of participants at the time of their stroke, overall and
stratiﬁed by stroke subtype, are displayed in Table 1.
3.2. Incidence of Stroke Subtypes and Association With Hypertension
Over the follow-up period of 339,979 PYRS, there were 590 strokes
(IR: 1.74, 95% conﬁdence interval [CI] [1.60, 1.88]/1000 PYRS). Nearly
half of the strokes were ischemic, whereas around two-thirds and
one-third, respectively, were of unknown and hemorrhagic origin
(Table 2). The crude IRs for stroke, overall and for each sub-type, were
higher in those with hypertension than in those without (Table 2).
3.3. Exploratory Analysis of Stroke Risk Factors for Ischemic and Hemor-
rhagic Stroke
Poisson regression models suggested that the risk factor proﬁle for
the two main stroke subtypes differed (Fig. 1). Ischemic strokes ap-
peared to be more strongly associated with traditional CVD risk factors
(male gender, dyslipidemia, previous CVD, diabetes, smoking) and pre-
vious AIDS thanwere hemorrhagic strokes. Conversely, while hyperten-
sion was associated with both stroke subtypes, its association appeared
to be stronger for hemorrhagic strokes than for ischemic strokes (ad-
justed relative rate 3.53 [2.23–5.58] for ischemic and 2.10 [1.65–2.65]
for hemorrhagic) (Fig. 1a), a similar pattern to that seen for a CD4
count b200 cells/μL.WhileHCV andHBV both appeared to be associated
(non-signiﬁcantly so) with an increased risk of hemorrhagic stroke,
their associations with ischemic stroke appeared to be in the opposite
direction (Fig. 1b).
3.4. Formal Comparison of Risk Factors for Hemorrhagic and Ischemic
Strokes
In line with our exploratory analyses, hypertension appeared to be a
stronger risk factor for hemorrhagic than ischemic strokes, although the
association was of only borderline signiﬁcance (Table 3). Other risk fac-
tors that appeared to differ signiﬁcantly in their predictive ability for ei-
ther stroke subtype were male gender, current smoking and a previous
CVDevent, each ofwhich appeared to be stronger predictors of ischemic
than hemorrhagic strokes (Table 3). Conversely, IDUmode of HIV infec-
tion and anti-HCV positivity/HCV infection were signiﬁcantly stronger
predictors for hemorrhagic than for ischemic strokes. Of the HIV-
related factors, a current CD4 count b200 cells/μL was a stronger risk
factor for hemorrhagic strokes than for ischemic strokes although the
difference in predictive ability was only borderline signiﬁcant (Table 3).
In a further model which allowedmore than one risk factor to inter-
act with the stroke outcomes simultaneously (Table 4), the association
for hypertensionwas strengthened andwas a signiﬁcantly stronger pre-
dictor for hemorrhagic than ischemic strokes. It also became clear that
the difference seen in the association with IDU status was largely ex-
plained by a higher rate of anti-HCV positivity in those infected through
IDU. In this full multivariable model, therefore, the difference in
Table 1
Characteristics of all study participants at baseline and at time of stroke, overall and stratiﬁed by stroke type.
At study entry At time of stroke
N (%) Total Hemorrhagic Ischemic Unknown
N (%) N (%) N (%) N (%)
Total number of participants 43,564 590 83 296 211
Demographic/CVD-related
Gender Male 32,064 (73.6) 481 (81.5) 56 (67.5) 251 (84.8) 174 (82.5)
Age (years) Median (IQR) 39 (33–46) 55 (46–64) 52 (46–59) 55 (46–63) 54 (46–63)
Ethnicity White 22,418 (51.5) 310 (52.5) 37 (44.6) 142 (48.0) 131 (62.1)
Smoking status Current smoker 18,250 (41.9) 262 (44.4) 34 (41.0) 145 (49.0) 83 (39.3)
Ex-smoker 7648 (17.6) 140 (23.7) 22 (26.5) 64 (21.6) 54 (25.6)
Never/unknown 17,666 (40.6) 188 (31.9) 27 (32.5) 87 (29.4) 74 (35.1)
Previous CVD event Yes 662 (1.5) 108 (18.3) 7 (8.4) 55 (18.6) 46 (21.8)
Family history of CVD Yes 3100 (7.1) 67 (11.4) 9 (10.8) 37 (12.5) 21 (10.0)
Hypertension Yes 10,281 (23.6) 293 (49.7) 49 (59.0) 150 (50.7) 94 (44.6)
Diabetes Yes 1340 (3.1) 95 (16.1) 9 (10.8) 54 (18.2) 32 (15.2)
Dyslipidemia Yes 17,490 (40.2) 351 (59.5) 44 (53.0) 181 (61.2) 126 (59.7)
BMI (kg/m2) Median (IQR) 23 (21–25) 23 (21–26) 23 (21–27) 23 (21–26) 23 (21–26)
eGFR (mL/min/L.72 m3) Median (IQR) 104 (89–121) 84 (67–99) 80 (62–98) 83 (67–100) 85 (71–100)
HIV-related
Previous AIDS event Yes 10,019 (23.0) 237 (40.2) 33 (39.8) 126 (42.6) 78 (37.0)
Ever received ART Yes 30,089 (69.1) 565 (95.8) 79 (95.2) 288 (97.3) 198 (93.8)
Mode of HIV-acquisition MSMa 19,183 (44.0) 266 (45.1) 30 (36.1) 135 (45.6) 101 (47.9)
IDU 6580 (15.1) 82 (13.9) 17 (20.5) 35 (11.8) 30 (14.2)
Heterosexual 15,126 (34.7) 192 (32.5) 29 (34.9) 97 (32.8) 66 (31.3)
Other/unknown 2675 (6.1) 50 (80.5) 7 (8.4) 29 (9.8) 14 (6.6)
CD4 (cells/μL) Median (IQR) 423 (270–610) 446 (250–650) 455 (262–760) 461 (270–688) 390 (213–600)
HIV RNA (log10 copies/mL) Median (IQR) 2.5 (1.7–4.2) 1.7 (1.7–2.5) 1.7 (1.7–2.1) 1.7 (1.7–2.2) 1.7 (1.7–3.0)
HCV positiveb Positive 7686 (17.6) 113 (19.2) 26 (31.3) 44 (14.9) 43 (20.4)
HBV positivec Positive-active 1962 (4.5) 15 (2.5) 4(4.8) 9 (3.0) 2 (1.0)
IDU: injection drug use;MSM:menwho have sexwithmen; BMI: bodymass index; eGFR: estimated glomerularﬁltration rate; PI: protease inhibitor; NNRTI: non-nucleoside transcriptase
inhibitor; NRTI: nucleoside transcriptase inhibitor.
a MSM: men who have sex with men.
b HCV-antibody positive and/or HCV-RNA positive.
c HB surface antigen, HBe antigen or HBV DNA+ positive.
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association with IDU between the two stroke subtypes was reduced
substantially and was no longer signiﬁcant.
3.5. Sensitivity Analyses
An eGFR b60 mL/min/1.72 m3 appeared to be more strongly associ-
ated with hemorrhagic thanwith ischemic strokes (hemorrhagic stroke
2.85 [1.45–5.64] vs. ischemic stroke 1.00 [0.68–1.48]) in exploratory
analyses, a ﬁnding which was conﬁrmed in the formal comparison
model (4.81 [2.47–9.36] vs. 1.04 [0.67–1.59], pequal b 0.001). Our conclu-
sionswere not signiﬁcantly changedwhen re-deﬁning hypertension on
the basis of two consecutive elevated BP measurements (data not
shown).
4. Discussion
In this large, observational study of PLWHIV, we observed several
differences in the risk factor proﬁles for ischemic and hemorrhagic
strokes. Firstly, while hypertension and agewere the strongest common
risk factors for both stroke subtypes, ischemic strokes appeared to be
more strongly linked to male gender, smoking, previous CVD events
and metabolic risk factors whereas hemorrhagic strokes appeared to
be more strongly linked to hypertension, a low CD4 count, anti-HCV
positivity and, in a smaller sub-analysis, renal impairment. While our
study was limited by the number of stroke events, particularly hemor-
rhagic strokes,we did ﬁnd a statistically signiﬁcant difference for hyper-
tension, gender, smoking, previous CVD events, HCV and renal
impairment.
Hypertension is recognized as a major risk factor for both types of
stroke [15], but has been observed to be a stronger predictor for hemor-
rhagic than ischemic strokes in the general population [15,17]. We ob-
served a similar difference in the association between hypertension
and each stroke-subtype (3-fold higher for hemorrhagic but 2-fold
higher for ischemic) as has been reported in the general population;
the difference was statistically signiﬁcant when associations were for-
mally compared.
The aging HIV population represents a new clinical challenge due to
a higher prevalence of CVD risk factors, comorbidities and
polypharmacy. The risk of stroke steadily increases with age [1]; as in
the general population [15], our analyses suggested that the predictive
ability of age did not differ greatly by stroke type.While our exploratory
analyses suggested that metabolic factors, including diabetes, dyslipid-
emia and BMI, were more strongly associated with ischemic than hem-
orrhagic strokes in PLWHIV, largely consistent with ﬁndings from the
general population [15], differences in predictive abilitywere not signif-
icantwhen tested formally, possibly reﬂecting a reduction in power due
to the small number of hemorrhagic strokes included.
Whilemale genderwas a signiﬁcantly stronger predictor of ischemic
than hemorrhagic strokes in our analyses, as reported in the general
population [15], female gender appeared to be a stronger predictor for
hemorrhagic stroke. Similar ﬁndings in PLWHIV have been reported
by Chow et al. [3].
A previous CVD event was a signiﬁcantly stronger predictor for is-
chemic strokes, potentially due to fewer prior hemorrhagic events
that also have higher fatality rates [1]. Suboptimal medical secondary
prophylaxis has been reported in PLWHIV [20] emphasizing the impor-
tance of optimizing CVD risk prevention and treatment.
Current smokingwas associatedwith an almost 2-fold increased risk
of ischemic strokes and was a signiﬁcantly stronger predictor of these
than hemorrhagic strokes. Although smoking is an important risk factor
for both stroke types in the general population, studies have generally
indicated a stronger association with ischemic stroke [15,21]. It is un-
clear why we do not ﬁnd an association between current smoking and
hemorrhagic stroke in our HIV cohort, although this may be a conse-
quence of reduced power due to the small number of such events.
While IDU was a stronger predictor for hemorrhagic strokes, the as-
sociation appeared to be primarily driven by concomitant HCV infec-
tion, which appeared to be a potential risk factor for hemorrhagic
stroke but was strongly associated with a reduced risk of ischemic
stroke. In contrast, a similar increased risk has been observed between
HCV infection and both hemorrhagic [22] and ischemic strokes [23] in
the general population. In PLWHIV, HCV has been reported to be a
strong predictor for hemorrhagic strokes [14], as has an increased risk
of composite endpoints of cerebro/cardiovascular nature with HIV/
HCV co-infection [24], suggesting a persistent inﬂammatory state
where HIV and HCV may act synergistically [24]. For hemorrhagic
strokes speciﬁcally, the inﬂammation-induced vasculitis changes in ce-
rebral arteries associatedwith other viruses (varicella zoster virus, cyto-
megalovirus and HIV) may trigger bleeding [25], as can the coagulation
abnormalities associated with severe HCV-disease manifestations [26].
The lack of an association between HCV and ischemic stroke in our
studymight reﬂect a selection of HCV co-infected individuals in our co-
hort with more severe HCV disease at higher risk of bleeding. More re-
search is needed to further examine the nature of these associations
and whether eradication of HCV with direct acting antivirals can revert
this risk in PLWHIV. However, our ﬁndings along with previous studies
argue that HCV-monitoring should be included in CVD risk screening
and that HCV-treatment should potentially be considered in all HIV/
HCV-infected individuals regardless of HCV disease stage.
In contrast to HCV, no signiﬁcant association has previously been
demonstrated between HBV and increased CVD risk in PLWHIV [6]. In
our analysis, a small apparent difference in predictive risk of HBV with
the different stroke subtypes was not seen in themodel allowingmulti-
ple factors to vary simultaneously, which is consistent with previous
data [6].
Previous reports on the impact of both CD4 count and HIV VL on is-
chemic stroke risk or composite stroke endpoints in PLWHIV have been
conﬂicting [2,4,6,8]. In unadjusted analyses, we observed a strong asso-
ciation between low current CD4 count and increased risk of hemor-
rhagic stroke but not ischemic stroke, although the difference in
predictive ability was non-signiﬁcant and the CD4 count did not meet
our threshold for inclusion in the ﬁnal multivariable model. While we
cannot rule out the possibility that an association was missed due to a
lack of power, and as such any conclusions must be made with caution,
these results are consistent with some previous studies [3,14]. Further-
more, rigorous validation methods in our cohort reduce the risk of in-
cluding AIDS-related conditions mimicking stroke, arguing that HIV-
related intracerebral immune-deﬁciency may indeed increase the risk
of hemorrhagic stroke. Biological mechanisms behind increased hemor-
rhagic stroke riskwith low CD4 countmay be explained by two types of
Table 2
Incidence of any stroke and each stroke subtype (/1000 PYRS) overall and stratiﬁed by the presence or absence of hypertension.
Type of strokea Overall No hypertension Hypertension
N stroke events/PYRS Rate/1000 PYRS (95% CI) N stroke events/PYRS Rate/1000 PYRS (95% CI) N stroke events/PYRS Rate/1000 PYRS (95% CI)
All 590/339,979 1.74 (1.60, 1.88) 297/255133 1.16 (1.03, 1.30) 293/84,850 3.45 (3.06, 3.85)
Hemorrhagic 83/341,962 0.24 (0.19, 0.30) 34/256,307 0.13 (0.09, 0.18) 49/85,660 0.57 (0.41, 0.73)
Ischemic 296/340,995 0.87 (0.77, 0.97) 148/255,698 0.58 (0.49, 0.67) 148/85,297 1.74 (1.46, 2.02)
Unknown 211/341,357 0.62 (0.54, 0.70) 115/255,939 0.45 (0.37, 0.53) 96/85,424 1.12 (0.90, 1.35)
a Stroke event censored after ﬁrst hemorrhagic/ischemic stroke event.
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arterial remodeling; endothelial dysfunction related to immunosup-
pression and inﬂammation leading to the destructive process by
lipohyalinosis affecting cerebral small vessels [3], and a non-
atherosclerotic dolichoectatic arterial phenotype previously associated
with prolonged immune impairment in HIV [12,27]. Immune reconsti-
tutionmay also affect the arterialwall leading to increased risk of stroke
Fig. 1. a: Association betweendemographic and CVD-related factors, exploratorymultivariable Poissonmodels for 83 hemorrhagic and 296 ischemic strokes. Footnotes: Reference groups:
Male gender: Female gender; Previous CVD:NopreviousCVD; Smoking: never smoked; Hypertension:Nohypertension;Diabetes:Nodiabetes; Dyslipidemia:Nodyslipidemia; bodymass
index (BMI): 18–25. Additionally adjusted for: Age, elevated BP, gender, BMI, smoking, previous CVD, diabetes, dyslipidemia. 1: HCV-antibody pos./HCV-RNA pos. 2: Active [HB surface
antigen, HBe antigen or HBV DNA+ pos.]. b: Association between HIV-related factors and stroke, exploratory multivariable Poisson models for 83 hemorrhagic and 296 ischemic
strokes. Footnotes: Reference groups: Injection drug use (IDU): Men who have sex with men; previous AIDS: No previous AIDS; CD4 count: CD4 count N 200 cells/μL; protease
inhibitors (PIs): Never exposed to PIs; non-nucleoside reverse transcriptase inhibitors (NNRTIs): Never exposed to NNRTIs; nucleoside reverse transcriptase inhibitors (NRTIs): Never
exposed to NRTIs; hepatitis C (HCV): Never HCV positive; hepatitis B (HBV): Never HBV positive. Additionally adjusted for: Mode of HIV-infection, CD4 count, exposure to ART,
previous AIDS.
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after start of ARVs [13,28], which may argue for increased attention to
stroke prevention in PLWHIV with low CD4 nadir and subsequent im-
mune reconstitution. Conversely, we did not observe a signiﬁcantly in-
creased risk of either stroke type with a detectable VL (N500 copies/mL).
Increased stroke risk has previously been associated with abacavir
use [4,6] and cumulative PI exposure [9]. In our study, including a larger
number of stroke events and adjustment for potential confounders, no
association was observed between cumulative exposure to ARVs and
Table 3
Association between each potential risk factor and stroke when each parameter is included in a separate competing risk model.a
Risk factor Event Hazard ratio 95%
conﬁdence
interval
Hazard ratio p value p-Value for overall average effectb p-Value for test of equal effectsc
Age/5 years Hemorrhagic 1.28 1.17 1.39 b0.001 b0.001 0.14
Ischemic 1.19 1.12 1.25 b0.001
Gender Male Hemorrhagic 0.56 0.35 0.91 0.020 b0.001 b0.001
Ischemic 1.62 1.14 2.31 0.008
Female 1.00 – – –
Hypertension Yes Hemorrhagic 3.55 2.29 5.50 b0.001 b0.001 0.070
Ischemic 2.24 1.77 2.84 b0.001
No 1.00 – – –
Previous CVD event Yes Hemorrhagic 1.44 0.66 3.16 0.34 b0.001 0.016
Ischemic 4.03 2.91 5.57 b0.001
No 1.00 – – –
Dyslipidemia Yes Hemorrhagic 0.97 0.63 1.49 0.88 0.006 0.10
Ischemic 1.48 1.16 1.83 0.001
No 1.00 – – –
Diabetes Yes Hemorrhagic 1.21 0.57 2.43 0.60 0.008 0.42
Ischemic 1.65 1.20 2.27 0.002
No 1.00 – – –
Mode of HIV infection IDU Hemorrhagic 2.68 1.38 5.17 0.004 0.002 0.040
Ischemic 1.37 0.82 2.29 0.22
MSM 1.00 – – –
Heterosexual 1.27 0.97 1.67 0.083
Missing 1.62 1.12 2.33 0.010
BMI (kg/m2) b18 Hemorrhagic 1.79 0.72 4.48 0.21 0.20 0.65
Ischemic 1.41 0.85 2.34 0.18
18, b26 1.00 – – –
26, b30 0.79 0.58 1.06 0.11
≥30 1.09 0.71 1.66 0.69
Missing 0.58 0.34 0.97 0.039
Smoking status Yes Hemorrhagic 1.08 0.68 1.71 0.75 b0.001 0.030
Ischemic 1.90 1.41 2.56 b0.001
Ex-smoker 1.04 0.76 1.43 0.82
Never 1.00 – – –
Missing 1.47 1.00 2.17 0.048
HIV RNA (copies/mL) N500 Hemorrhagic 1.03 0.58 1.82 0.92 0.22 0.34
Ischemic 1.36 0.96 1.94 0.083
≤500 1.00 – – –
CD4 count (cells/μL) b200 Hemorrhagic 1.94 1.09 3.45 0.025 0.082 0.065
Ischemic 1.03 0.69 1.53 0.89
≥200 1.00 – – –
PI exposure/5 years Hemorrhagic 1.10 0.70 1.74 0.66 0.90 0.70
Ischemic 0.98 0.74 1.31 0.91
NNRTI exposure/5 years Hemorrhagic 0.80 0.51 1.27 0.35 0.12 0.76
Ischemic 0.74 0.55 0.10 0.050
NRTI exposure/5 years Hemorrhagic 1.25 0.62 2.51 0.54 0.12 0.72
Ischemic 1.44 1.00 2.08 0.048
Previous AIDS event Yes Hemorrhagic 1.33 0.85 2.09 0.22 0.013 0.89
Ischemic 1.38 1.09 1.74 0.007
No 1.00 – – –
HCV positived No 1.00 – – –
Yes Hemorrhagic 1.32 0.72 2.40 0.37 b0.001 b0.001
Ischemic 0.46 0.23 0.70 b0.001
Unknown 1.57 0.70 2.48 0.052
HBV positivee No 1.00 – – –
Yes (active) Hemorrhagic 1.19 1.12 1.25 b0.001 0.76 0.076
Ischemic 1.22 0.90 1.65 0.12
Yes (inactive) Hemorrhagic 2.47 2.01 3.04 b0.001 0.46 0.35
Ischemic 3.35 2.48 4.54 b0.001
Unknown 1.33 1.09 1.63 0.006
CVD: cardiovascular disease; IDU: injection drug use; MSM: menwho have sex with men; BMI: bodymass index; PI: protease inhibitor; NNRTI: non-nucleoside reverse transcriptase in-
hibitor; NRTI: nucleoside reverse transcriptase inhibitor; HCV: hepatitis C virus; HBV: hepatitis B virus.
a The parameter estimates displayed in the table arise from a series of separate competing risk Cox proportional hazardmodels inwhich the associationwith the indicated parameter is
allowed to vary by stroke subtype (all other factors in the model are assumed to have the same association with each stroke subtype).
b The p-value for the overall average effect tests the null hypothesis that there is no overall association between the parameter and stroke.
c The p-value for equal effects tests the null hypothesis that the association between the parameter and stroke is the same for the two stroke subtypes (with rejection of the null hy-
pothesis if p b 0.05, suggesting that any difference in the predictive value for the two stroke subtypes was unlikely to be a chance ﬁnding).
d HCV-antibody positive and/or HCV-RNA positive.
e HB surface antigen, HBe antigen or HBV DNA+ positive.
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increased risk of any of the two stroke subtypes. Although clinicians
may havemoved away fromolder ARVs known to be associatedwith in-
creased CVD risk, our ﬁndings are supported by several other previous
studies [2,3,6,8,29], and the overall evidence for ARV exposure as a sig-
niﬁcant stroke risk factor seems scarce.
We found low eGFR to be a signiﬁcantly stronger predictor for hem-
orrhagic than ischemic strokes, with similar risk estimates previously
reported in the general population [16]. Adjustment for other CVD risk
factors did not markedly affect the eGFR estimate, possibly implying a
causal relationship between low eGFR and hemorrhagic stroke; low
eGFR may induce platelet dysfunction leading to prolonged bleeding
time and increasing risk of cerebral hemorrhages [16], or be correlated
with cerebral small vessel disease, the mechanism behind most brain
hemorrhages [16,30]. We have previously demonstrated associations
between lower eGFRs and composite endpoints of CVD [7] and current
ﬁndings emphasize the importance of renal monitoring in overall CVD
risk assessment.
4.1. Limitations
Although our number of hemorrhagic strokes was higher than in
most other studies in PLWHIV, [3,14] and our ﬁndings were broadly
consistent with other published studies, both in the general population
and in PLWHIV, the relatively small number of eventsmay have reduced
our power to detect clinically important differences in the predictive
ability of risk factors, urging a conservative interpretation of our ﬁnd-
ings. As our primary interestwas in the potential impact of uncontrolled
hypertension, we did not investigate whether treated individuals with
normalized BPmight remain at higher risk of stroke. Analyses of treated
hypertension in an international and multi-center cohort collaboration
such as the D:A:D Study will be limited by variations in the diagnosis
and treatment of hypertension, as well as the frequency of blood pres-
sure monitoring, which are all likely to vary by country and clinic. For
this reason, our analyses deliberately considered a simple deﬁnition of
hypertension based on a single elevated blood pressure assessment
only. However, sensitivity analyses which considered a more conserva-
tive deﬁnition (based on the requirement for two consecutive blood
pressure assessments to be elevated) reached similar conclusions. Un-
fortunately, we do not have access to information on the subtypes of
any ischemic strokes whichwould permit us to undertakemore precise
risk estimation and we do not systematically collect some stroke risk
factors such as atrial ﬁbrillation, heart failure, alcohol abuse or inﬂam-
matorymarkers thatmay play a role in stroke risk. Despite extensive ef-
forts to obtain complete data on HCV coinfection, this information is
missing for a proportion of participants whichmay restrict our analyses
of associations with this infection. Finally, as with any observational
study, unmeasured or residual confounding may have inﬂuenced our
ﬁndings.
In summary, the risk factor proﬁles for ischemic and hemorrhagic
strokes in PLWHIV appear to differ. While we found no strong evidence
to support the need for speciﬁc stroke risk prediction scores for
PLWHIV, our ﬁndings do emphasize the importance of considering
stratiﬁed stroke risk prediction for the different stroke subtypes to opti-
mize preventive measures and screening. Further studies are needed to
conﬁrm our ﬁndings in order to provide more precise risk scoring sys-
tems in PLWHIV as well as in the general population.
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Table 4
Association between each risk factor and stroke when parameters are ﬁtted in a single competing risks model.a
Risk factor Category Stroke subtype Hazard ratio 95%
conﬁdence
interval
p value p-Value for overall average effectb p-Value for test of equal effectsc
Age/5 years 1.20 1.14 1.26 b0.001
Gender Male Hemorrhagic 0.62 0.39 1.01 0.054 0.004 0.001
Ischemic 1.59 1.11 2.27 0.011
Female 1.00 – – –
Hypertension Yes Hemorrhagic 3.96 2.560 6.11 b0.001 b0.001 0.021
Ischemic 2.22 1.78 2.81 b0.001
No 1.00 – – –
Previous CVD event Yes Hemorrhagic 1.61 0.73 3.56 0.24 b0.001 0.039
Ischemic 3.91 2.83 5.41 b0.001
No 1.00 – – – –
Mode of HIV infection MSM 1.00 – – –
IDU Hemorrhagic 1.58 0.60 4.17 0.36 0.079 0.89
Ischemic 1.75 1.04 2.95 0.035
Heterosexual 1.34 1.03 1.76 0.032
Missing 1.89 1.30 2.69 0.001
Smoking status Current Hemorrhagic 0.96 0.59 1.61 0.92 b0.001 0.013
Ischemic 1.93 1.43 2.5 b0.001
Ex-smoker 0.78 0.57 1.05 0.10
Never 1.00 – – –
Unknown 1.43 0.93 2.20 0.10
HCV positived No 1.00 – – –
Yes Hemorrhagic 1.54 0.70 3.40 0.28 b0.001 0.006
Ischemic 0.43 0.27 0.68 0.000
Unknown Hemorrhagic 1.60 0.79 3.22 0.19 0.14 0.97
Ischemic 1.57 0.92 2.69 0.10
CVD: cardiovascular disease; IDU: injection drug use; MSM: men who have sex with men; HCV: hepatitis C virus; HBV: hepatitis B virus.
a The parameter estimates displayed in the table arise froma single Cox proportional hazardmodel inwhich all associationswith the indicated parameters are allowed to vary by stroke
subtype simultaneously.
b The p-value for the overall average effect tests the null hypothesis that there is no overall association between the parameter and stroke.
c The p-value for equal effects tests the null hypothesis that the association between the parameter and stroke is the same for the two stroke subtypes (with rejection of the null hy-
pothesis if p b 0.05, suggesting that any difference in the predictive value for the two stroke subtypes was unlikely to be a chance ﬁnding).
d HCV-antibody positive and/or HCV-RNA positive.
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